Rebuma Firdessa Fite

Dr. Rebuma Firdessa Fite is an Assistant Professor in the Department of Microbiology & Immunology and the Department of Medicine (Endocrinology) at Albert Einstein College of Medicine. Her research focuses on nanomedicine and precision medicine approaches to combat type 1 diabetes (T1D), with a particular emphasis on antigen-specific immunotherapy. She leads the NanoImmunology laboratory, which explores three core areas: 1) pMHC-TCR binding properties, 2) novel nanodelivery systems for antigens, and 3) improved human immune system (HIS) mouse models for T1D. Dr. Fite collaborates with institutions like Washington University to advance nanotechnology in immunotherapy. Her work has been published in high-impact journals including Frontiers in Immunology and Proceedings of the National Academy of Sciences.

Her research integrates molecular immunology, nanotechnology, and translational medicine to address autoimmune mechanisms in T1D. Key contributions include demonstrating that soluble antigen arrays (SAgAs) enhance therapeutic efficacy in preclinical models compared to free peptides. She also develops HIS mouse models to better simulate human immune responses. Dr. Fite’s lab emphasizes understanding T cell interactions with neoantigens and designing targeted delivery systems to induce immune tolerance.

No scientific awards are explicitly listed in available texts. Her research is funded through collaborations and institutional resources, though specific grants are not detailed here. The lab’s work has implications for advancing therapies targeting autoimmune diseases and improving preclinical models for human immune studies.